More News
Want to Read Locked Articles?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.
EU Regulators Approve Vevizye from Novaliq; Théa Will Commercialize Dry Eye Drop
Author: Jennie Crabbe
Germany’s Novaliq announced Oct. 2 that the European Commission had approved its dry eye treatment Vevizye (cyclosporine ophthalmic solution) 0.1%.
The product is indicated for the treatment of moderate to severe dry eye disease in adults who have not seen improvement with the use of artificial tears.
The company also announced that France’s Laboratoires Théa had acquired the rights to commercialize Vevizye in Europe and selected countries in the Middle East and North Africa.
No financial details were disclosed.
The treatment is marketed in the US by Harrow as Vevye. It was approved by the US FDA in May 2023 and launched in January 2024. Harrow also holds Canadian rights.
Vevizye is a non‑preserved, twice-daily-dosed eye drop based on Novaliq’s water‑free semifluorinated alkane technology. It combines the inhibition of tear evaporation with the anti-inflammatory properties of cyclosporine to treat both the signs and symptoms of dry eye.
Novaliq also developed Miebo (perfluorohexyloctane), a dry eye drop targeting tear evaporation that is marketed in the US by Bausch + Lomb.
